← Back to Patent Explorer
US4382081A Expired / Lapsed US ⏱️ 0.0 years remaining

Inhibitors of mammalian collagenase

Assignee: ERSQUIBB & SONS Inc A CORP OF
•
Filing: 1981-06-12
•
Granted: 1983-05-03
•
Expires: 2001-06-12
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Mammalian collagenase is inhibited by compounds of the formula ##STR1## or salts thereof, wherein R is hydrogen, alkanoyl of 2 to 10 carbon atoms or arylcarbonyl; R 1 is of 3 to 8 carbon atoms, cycloalkyl of 3 to 7 carbon atoms, aryl or arylalkyl; ##STR2## R 4 is hydrogen, methyl, ethyl, or ##STR3## R 5 and R 6 are each independently selected as --OCH 3 or --OCH 2 CH 3 or are combined as --OCH 2 CH 2 O-- or --O--(CH 2 )--O--; R 7 and R 8 are each independently selected as hydrogen, methyl or ethyl or are combined as --(CH 2 ) 4 --, --(CH 2 ) 5 -- or --CH 2 CH 2 --O--CH 2 CH 2 --; R 9 is hydrogen, methyl, ethyl ##STR4## m is an integer from 0 to 7; p is an integer from 1 to 3; AA n is an amino acid chain of from one to three amino acids; n is 1 or 1, 2 or 1, 2, 3; when p is 1, AA n is AA 1 ; when p is 2, AA n is AA 1 --AA 2 ; when p is 3, AA n is AA 1 --AA 2 --AA 3 ; AA 1 is glycine or alanine; AA 2 is glycine or alanine; AA 3 is leucine, glutamine or isoleucine. A method of reducing the adverse effects of mammalian collagenase in a mammalian host in need thereof, which comprises administering to the mammal an effective amount of a compound having the above formula is within the scope of the invention.

Inventors

  • 👤 Joseph E. Sundeen
  • 👤 Tamara Dejneka

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-04 17:07
CPC Classifications
C; C07; C07K; C07K5/00; C07K5/04; C07K5/10; C07K5/1002; C07K5/1005; C07K5/1008; C07C; C07C323/00; C07C323/50; C07C323/51; C07C323/52; C07C323/56; C07C327/00; C07C55/00; C07C55/02; C07K5/06; C07K5/06008; C07K5/06017; C07K5/06026; C07K5/08; C07K5/0802; C07K5/0804; C07K5/0806

Claims Analysis

Total Claims: 11
Claim 1
Independent Claim 250 words
A compound of the formula ##STR186## or salts thereof wherein R is hydrogen, alkanoyl of 2 to 10 carbon atoms or arylcarbonyl; R 1 is alkyl of 3 to 8 carbon atoms, cycloalkyl of 3 to 7 carbon atoms, aryl or arylalkyl; R 2 is hydrogen or ##STR187## R 3 is ##STR188## R 4 is hydrogen, lower alkyl or arylalkyl; R 5 and R 6 are each independently selected as --OCH 3 or --OCH 2 CH 3 or are combined as --OCH 2 --CH 2 --O-- or --O--(CH 2 ) 3 --O--; R 7 and R 8 are each independently selected as hydrogen, lower alkyl or are combined as --(CH 2 ) 4 --, --(CH 2 ) 5 -- or --CH 2 CH 2 --O--CH 2 CH 2 --; R 9 is hydrogen, lower alkyl, ##STR189## m is an integer from 0 to 7; p is an integer from 1 to 3 with the proviso that when p is 1, R 2 is -(lower alkyl) ##STR190## AA n is an amino acid chain or from one to three amino acids; n is 1 or 1, 2 or 1, 2, 3; when p is 1, AA n is AA 1 ; when p is 2, AA n is AA 1 --AA 2 ; when p is 3, AA n is AA 1 --AA 2 --AA 3 ; AA 1 is glycine or alanine; AA 2 is glycine or alanine; AA 3 is leucine, glutamine or isoleucine, and physiologically acceptable salts thereof.
Claim 2
Dependent Claim 250 words
A compound of the formula ##STR186## or salts thereof wherein R is hydrogen, alkanoyl of 2 to 10 carbon atoms or arylcarbonyl; R 1 is alkyl of 3 to 8 carbon atoms, cycloalkyl of 3 to 7 carbon atoms, aryl or arylalkyl; R 2 is hydrogen or ##STR187## R 3 is ##STR188## R 4 is hydrogen, lower alkyl or arylalkyl; R 5 and R 6 are each independently selected as --OCH 3 or --OCH 2 CH 3 or are combined as --OCH 2 --CH 2 --O-- or --O--(CH 2 ) 3 --O--; R 7 and R 8 are each independently selected as hydrogen, lower alkyl or are combined as --(CH 2 ) 4 --, --(CH 2 ) 5 -- or --CH 2 CH 2 --O--CH 2 CH 2 --; R 9 is hydrogen, lower alkyl, ##STR189## m is an integer from 0 to 7; p is an integer from 1 to 3 with the proviso that when p is 1, R 2 is -(lower alkyl) ##STR190## AA n is an amino acid chain or from one to three amino acids; n is 1 or 1, 2 or 1, 2, 3; when p is 1, AA n is AA 1 ; when p is 2, AA n is AA 1 --AA 2 ; when p is 3, AA n is AA 1 --AA 2 --AA 3 ; AA 1 is glycine or alanine; AA 2 is glycine or alanine; AA 3 is leucine, glutamine or isoleucine, and physiologically acceptable salts thereof.
Claim 3
Dependent Claim 19 words
A compound of claim 1 wherein R is hydrogen, R 3 is ##STR191## and m is 0 to 3.
Claim 4
Dependent Claim 9 words
A compound of claim 2 wherein n is 3.
Claim 5
Dependent Claim 9 words
A compound of claim 3 having the name N-[N-[[N-[2-(mercaptomethyl)-4-methyl-1-oxopentyl]-L-alanyl]glycyl]-L-leucyl]-L-arginine.
Claim 6
Dependent Claim 13 words
The compound of claim 1 having the name (±)-N 2 -[N-[2-(mercaptomethyl)-4-methyl-1-oxopentyl]glycyl]-L-argininamide, monoacetate salt.
Claim 7
Dependent Claim 11 words
The compound of claim 1 having the name N 2 -[N-[N-[2-(mercaptomethyl)-4-methyl-1-oxopentyl]glycyl]glycyl]-L-arginine.
Claim 8
Dependent Claim 11 words
The compound of claim 1 having the name N 2 -[N-[N-[N-[2-(mercaptomethyl)-4-methyl-1-oxopentyl]glycyl]glycyl]-L-leucyl]-L-arginine.
Claim 9
Dependent Claim 26 words
A pharmaceutical composition for reducing the adverse effects of mammalian collagenase which comprises a compound as defined in claim 1 and a pharmaceutically acceptable carrier therefor.
Claim 10
Dependent Claim 34 words
A method for reducing the adverse effects of mammalian collagenase in a mammalian host in need thereof, which comprises administering to said mammal an effective amount of a compound as defined in claim 1.
Claim 11
Dependent Claim 24 words
A method for treating rheumatoid arthritis in a mammalian host, which comprises administering an effective amount of a compound as defined in claim 1.

References Cited (Backward Citations)

US4235885A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1986-05-02 1986-11-01 1987-05-03 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1990-05-02 1990-11-01 1991-05-03 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1994-05-02 1994-11-01 1995-05-03 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag